Amantadine for COVID-19: real-time analysis of 4 studies

Download Image

Post

c19early.org

Amantadine for COVID-19

3 studies with >500 patients

Serious outcome risk

Amantadine

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Amantadine studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (3)−19%

Mortality (2)0%

Hospitalization (1)−67%

Recovery (2)5%

RCTs (3)−19%

RCT mortality (2)0%

Late (3)−19%

00.511.5+

← Amantadine
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


	Covid Analysis	Meta-analysis of amantadine studies
	Meta-analysis of amantadine studies
Oct 31 2023	Weis et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2023.06.023	Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial
	48% worse recovery (p=0.1). RCT 242 non-hospitalized COVID-19 patients showing no benefit of amantadine for disease progression.
Sep 14 2023	Rejdak et al., European Journal of Neurology, doi:10.1111/ene.16045	Amantadine in unvaccinated patients with early, mild to moderate COVID‐19: A randomized, placebo‐controlled, double‐blind trial
	39% improved recovery (p=0.03) and 89% lower progression (p=0.12). RCT 99 patients showing higher complete recovery rates with amantadine, but no significant difference in progression. Authors suggest amantadine's central nervous system effects may have contributed to faster recovery by reducing neuropsy..
Jun 30 2023	Barczyk et al., Respiratory Medicine, doi:10.1016/j.rmed.2023.107198	Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study
	13% higher mortality (p=0.83) and 18% lower ICU admission (p=0.75). RCT 186 hospitalized COVID-19 patients showing no significant differences with oral amantadine compared to placebo.
Nov 30 2022	Chober et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.09.026	Improved survival in intensive care unit in severe COVID-19 associated with amantadine use - retrospective study
	Retrospective 241 COVID-19 ICU patients requiring mechanical ventilation showing significantly lower mortality with intravenous amantadine. However the KM plot shows very high control deaths on day 1 and no treatment deaths days 2-4. Give..